JPRN-UMIN000035533招募中未知
Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study - SBP-11
Setouchi Breast Project Comprehensive Support Organization0 个研究点目标入组 75 人开始时间: 2019年1月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1 with life-threatenings 2 symptomatic brain metastasis 3 eligible for inclusion criteria of PALOMA-3 4 pretreated with hormonal therapy for MBC 5 pregnancy or breast feeding or unwilling to contraception 6 long QT syndrome or similar diseases 7 Electrolyte abnormality causing long QT syndrome 8 uncontrolled hypertension, symptomatic heart failure, unstable angina, severe arrhythmia or acute myocardial infarction within 12 months 9 obvious pulmonary fibrosis or interstitial pneumonia 10 active infection 11 other severe comorbidity 12 another active cancer 13 allergic for fulvestrant or CDK4/6 inhibitor 14 other inappropriate patients
研究者
相似试验
尚未招募
不适用
Optimal therapeutic strategies with CDK4/6 inhibitors based on the real world evidence in patients with HR-positive/HER2-negative advanced and metastatic breast cancerHormone receptor positive HER2 negative advanced metastatic breast cancerJPRN-UMIN000051975Japan Breast Cancer Research Group(JBCRG)400
已完成
1 期
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.Advanced Solid TumorLymphomasNCT01237236Novartis Pharmaceuticals156
进行中（未招募）
不适用
eo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatmentEUCTR2014-001984-11-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E DELLA CURA DEI TUMORI32
进行中（未招募）
1 期
Endocrine therapy plus CDK4/6 inhibitor in first or second line for hormone receptor positive advanced breast cancerhormone receptor positive advanced breast cancerEUCTR2017-002334-23-NLDutch Breast Cancer Research Group (BOOG)1,050
已完成
不适用
Selecteren van de optimale plaats van CDK4/6-remmer bij de behandeling van uitgezaaide hormoongevoelige (HR+) borstkanker: de SONIA studiebreast cancerNL-OMON23699BOOG study center1,050